Adcon I

Drug Profile

Adcon I

Alternative Names: Adcon-I

Latest Information Update: 22 Dec 2003

Price : $50

At a glance

  • Originator Gliatech (CEASED)
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Post-surgical adhesions

Most Recent Events

  • 22 Dec 2003 Discontinued - Clinical-Phase-Unknown for Post-surgical adhesions in USA (Topical)
  • 26 Sep 2002 Gliatech is auctioning its Adcon® assets
  • 17 May 2002 Gliatech has filed a petition for bankruptcy protection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top